Description: MeTC7 is a VDR antagonist, which can be synthesized from 7-dehydrocholesterol (6) in two steps, inhibits VDR selectively, suppresses the viability of cancer cell-lines, and reduces the growth of the spontaneous transgenic TH-MYCN neuroblastoma and xenografts in vivo. Target: Others. Smiles:...

MeTC7 is a vitamin D receptor antagonist (IC50 = 2.9 µM in a fluorescence polarization assay). It inhibits vitamin D receptor transactivation in HEK293 cells (IC50 = 20.8 µM). It decreases the viability of OVCAR-8, OV-2008, SKOV3, Caov-3, and IGROV-1 ovarian cancer cells in a concentration-dependent manner. MeTC7...